Day: September 5, 2021

Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit

Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit

– One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients, as of the data cutoff – – Data presented today at the International Liver Cancer Association meeting at 12:25 p.m. CET – PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 05, 2021 (GLOBE NEWSWIRE) — Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, announced updated data from its Phase 1 ADP-A2AFP trial for patients with liver cancer at ILCA. “We have seen significant antitumor activity with this first-generation product targeting AFP that is encouraging for the potential of cell therapy for the treatment of liver cancer in these heavily pre-treated patients with late-stage disease,” said Elliot Norry, Adaptimmune’s Chief Medical Officer. “We reported a complete...

Continue reading